Drugs / M-M-R II vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06824181 Background | Feb 2025 → Sep 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M-M-R II vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06824181 ↗ |
| Modality | Vaccine | “M-M-R II vaccine” NCT06824181 ↗ |
| Route | Intramuscular | “Route of administration:Subcutaneous or Intramuscular” NCT06824181 ↗ |
| Route | Subcutaneous | “Route of administration:Subcutaneous or Intramuscular” NCT06824181 ↗ |